Paul Viney - Genetic Technologies CFO, COO, Company Secretary
| GENE Stock | USD 2.25 0.03 1.35% |
COO
Mr. Paul Keith Mathieson Viney is appointed as Chief Financial Officer, Chief Operating Officer, Company Secretary of the company effective December 27th 2018. He was most recently at Powerhouse Ventures in New Zealand and has over 15 years experience in governance and strategic leadership of mid and small cap ASX listed entities, coupled with a strong mix of industrial and medtech company experiences and sound VC knowledge He brings broad business acumen to the Company in addition to his strong foundation in finance, IT and corporate governance. since 2018.
| Tenure | 6 years |
| Address | 60-66 Hanover Street, Fitzroy, VIC, Australia, 3065 |
| Phone | 61 3 8412 7000 |
| Web | https://genetype.com |
Genetic Technologies Management Efficiency
The company has return on total asset (ROA) of (0.5271) % which means that it has lost $0.5271 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6047) %, meaning that it created substantial loss on money invested by shareholders. Genetic Technologies' management efficiency ratios could be used to measure how well Genetic Technologies manages its routine affairs as well as how well it operates its assets and liabilities. As of May 4, 2024, Return On Tangible Assets is expected to decline to -1.26. In addition to that, Return On Capital Employed is expected to decline to -1.04. At present, Genetic Technologies' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 10.6 M, whereas Total Current Assets are forecasted to decline to about 11.7 M.Similar Executives
| Found 1 records | COO Age | ||
| Adrienne Farid | Century Therapeutics | 62 | |
Management Performance
| Return On Equity | -1.6 | ||||
| Return On Asset | -0.53 |
Genetic Technologies Leadership Team
Elected by the shareholders, the Genetic Technologies' board of directors comprises two types of representatives: Genetic Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genetic. The board's role is to monitor Genetic Technologies' management team and ensure that shareholders' interests are well served. Genetic Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genetic Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Grahame Leonard, Director | ||
| Paul Viney, CFO, COO, Company Secretary | ||
| Mark Ostrowski, President of Phenogen Sciences Inc. | ||
| Diana Newport, Quality and Bus. Operations Director | ||
| CPA BCom, Chief Secretary | ||
| AGIA BCom, CFO Sec | ||
| Bus FCI, Consultant | ||
| Peter Rubenstein, Director | ||
| Justyn Stedwell, Company Secretary | ||
| Susan Gross, Senior Medical Director | ||
| Paul Kasian, Non-Executive Director | ||
| Bronwyn Christie, | ||
| Kevin Camilleri, Chief EasyDNA | ||
| Phillip Hains, CFO | ||
| Malcolm Brandon, Non-Executive Chairman of the Board | ||
| Eutillio Buccilli, CEO, Executive Director and Member of Remuneration Committee | ||
| Luisa Ashdown, Director of Global Licensing and Intellectual Property | ||
| Kevin Fischer, CFO | ||
| Lindsay Wakefield, Non-Executive Independent Director | ||
| Jerzy Muchnicki, Director | ||
| Xue Lee, Director | ||
| Simon Morriss, Chief Officer | ||
| Richard Allman, Scientific Director | ||
| Carl BSc, Chief Officer |
Genetic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genetic Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.6 | ||||
| Return On Asset | -0.53 | ||||
| Profit Margin | (1.24) % | ||||
| Operating Margin | (1.06) % | ||||
| Current Valuation | 256.87 M | ||||
| Shares Outstanding | 4.41 M | ||||
| Shares Owned By Institutions | 0.68 % | ||||
| Number Of Shares Shorted | 15.66 K | ||||
| Price To Earning | (1.87) X | ||||
| Price To Book | 4.08 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for Genetic Stock analysis
When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
Is Genetic Technologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genetic Technologies. If investors know Genetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genetic Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 2.73 | Quarterly Revenue Growth (0.02) | Return On Assets (0.53) | Return On Equity (1.60) |
The market value of Genetic Technologies is measured differently than its book value, which is the value of Genetic that is recorded on the company's balance sheet. Investors also form their own opinion of Genetic Technologies' value that differs from its market value or its book value, called intrinsic value, which is Genetic Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genetic Technologies' market value can be influenced by many factors that don't directly affect Genetic Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genetic Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Genetic Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genetic Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.